Menu
Company CEO, Todd O’Brien, recently delivered a lecture on diabetic peripheral neuropathy to the attendees at the Midwest Podiatry Conference in Chicago. “It was an honor to be asked to lecture at the Midwest.” Dr. O’Brien noted. ” Not only is this one of the best attended and most prestigious meetings in the US, it also afforded me the opportunity to connect with former classmates and teachers from podiatry school.”
The company is pleased to announce recent seed grant approval from the Maine Technology Institute (MTI). The award will be used to develop a proof-of-concept prototype designed to extend the feature set of the company’s core product, the ETF. Much of the work will be done in collaboration with the University of Maine’s Department of Chemical and Biomedical Engineering. Funding will also cover patent filing on the novel prototype.”We’re excited to work with MTI and UMaine to push the boundaries of clinical care diagnostics.” said company CEO, Todd O’Brien. ” The extended capabilities we’re developing for the ETF will provide a unique approach for assessing neuropathy in a point-of-care setting”.
ETFMx and ETF128
Company CEO, Todd O’Brien, recently presented a lecture at the APMA Region One Conference in Quincy, MA. His topic was an update on diabetic peripheral neuropathy and its clinical implications for medical professionals. The content of the talk was drawn from his own research and experience as well the latest findings from the medical literature. Approximately 200 podiatrists from the New England region were in attendance.
The company is pleased to announce the ETF’s selection as one of Podiatry Today’s Top Ten Innovations of 2014. “Inclusion in this list of emerging technological innovations is an unexpected honor, ” said company CEO, Todd O’Brien. “This is welcome recognition for our design team’s hard work especially as Podiatry Today is one of the most respected and widely read periodicals in the podiatry profession.”
The ETF, which has undergone three design iterations and a successful round of beta site testing, is currently scheduled for commercial launch in early 2015. Pre-orders are now being accepted for a limited pilot production run.
The company is pleased to announce the recent approval of it’s MTI Development Loan application. These funds will be used for further refinement of the ETF128 design as well as a pilot production run. Completion of the production run is expected by the end of 2014. The company looks forward to continuing its partnership with MTI as it launches the ETF into the marketplace.